Novel approaches, secondary analyses at forefront of upcoming AHA Scientific Sessions

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

growacet

Rank: Vice President [?]

Points: 13440 [?]

Votes: 55 Score: 3.2 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Novel approaches, secondary analyses at forefront of upcoming AHA Scientific Sessions

posted on Nov 14, 2019 02:41AM

From Cardiology Today....I don't know how big this site's footprint is, but exposure never hurts:

https://www.healio.com/cardiology/chd-prevention/news/online/%7B55cd41ff-e348-433b-8e20-5766fa1ee537%7D/novel-approaches-secondary-analyses-at-forefront-of-upcoming-aha-scientific-sessions

Several late-breaking clinical trials focus on novel approaches for medical therapy and intervention, including:

COLCOT, which is evaluating the use of colchicine in patients after MI to reduce rates of CV events;
Another trial will assess colchicine in patients after PCI;
EVAPORATE, in which researchers assessed the effect of icosapent ethyl (Vascepa, Amarin) on coronary atherosclerosis progression in patients with elevated triglycerides;
BETonMACE, a trial evaluating bromodomain and extraterminal domain protein inhibition with apabetalone in patients with ACS and diabetes; and
ORION-9 and ORION-10, two phase 3 trials analyzing the efficacy and safety of inclisiran (The Medicines Company) in patients with heterozygous familial hypercholesterolemia and with atherosclerotic CVD and elevated LDL, respectively.

5 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply